Developer docs
API playgroundTry for free, no card

Search company profiles

Tergus Pharma

Full company profile

uuid000adil

Namestring
Tergus Pharma
Legal namestring
Tergus Pharma
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Tergus Pharma is a US-based contract development and manufacturing organization (CDMO) founded in 1994 and headquartered in Durham, North Carolina, specializing in topical and transdermal pharmaceutical drug development and manufacturing. The company operates two Durham facilities — a research and innovation center on Emperor Boulevard supporting early-phase formulation development and a Stirrup Creek Drive site for clinical trial material supply and commercial GMP production — and serves pharmaceutical and biotech clients requiring specialized formulation, analytical, scale-up, and manufacturing services across dermal, ungual, ophthalmic, respiratory, mucosal, otic, gastrointestinal, and vaginal delivery routes.

The company's core technology stack centers on proprietary formulation science and in vitro performance testing platforms, including In Vitro Release Testing (IVRT) and In Vitro Permeation Testing (IVPT) models plus specialized nail permeation testing for keratinized tissue delivery. GMP manufacturing capabilities cover semi-solid and liquid drug products with particular strength in hormone-based compounds and highly potent active pharmaceutical ingredients, supported by an FDA inspection that returned a No Action Indicated (NAI) classification with zero Form 483 observations. The service portfolio spans formulation development, analytical and bioanalytical services, raw material and stability testing, research biology and tissue culture, scale-up and process development, clinical trial material manufacturing, commercial manufacturing, packaging and serialization, and generics and value-added generics development.

Tergus generated revenue through professional services engagements — fee-for-service drug development contracts, project-based GMP manufacturing agreements, and integrated development-to-commercial packages — sold via direct enterprise field sales to pharmaceutical and biotech procurement and R&D teams. Pricing was project-quoted based on scope, complexity, and volume, with multi-year contract cadences typical for late-stage and commercial supply relationships. In July 2024, Tergus merged with UK-based MedPharm, a CDMO with overlapping topical and transdermal specialization, with the combined entity now operating under the MedPharm name and offering transatlantic research, clinical supply, and commercial manufacturing capabilities.

Short descriptiontext

Tergus Pharma is a US-based contract development and manufacturing organization (CDMO) specializing in topical and transdermal drug formulation, analytical testing, and GMP manufacturing for pharmaceutical and biotech clients across multiple delivery routes; the company merged with UK-based MedPharm in July 2024 and now operates under the MedPharm name.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
topical drug development, transdermal CDMO services, pharmaceutical contract manufacturing, formulation development services, GMP commercial manufacturing
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Manufacturing Services
TypeProfessional Services
Description

GMP manufacturing services for semi-solid and liquid drug products supporting clinical trial material supply and commercial production. Revenue generated through project-based contracts with pharmaceutical and biotech companies requiring manufacturing scale-up and commercial supply capabilities.

medpharm.com
2Drug Development Services
TypeProfessional Services
Description

Formulation development, analytical services, bioanalytical services, stability storage and testing, in vitro performance testing (IVRT/IVPT), and process development. Revenue derived from fee-for-service engagements across the drug development lifecycle from early phase through regulatory submission.

medpharm.com
3Regulatory and Quality Services
TypeProfessional Services
Description

Quality assurance, regulatory standards support, validation studies, and regulatory submission preparation. Integrated as part of development and manufacturing service packages.

medpharm.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Project-based quoting for drug development and manufacturing services
ModelOtherBilling cadenceMulti-year contract
Notes

Services quoted based on project scope, development phase, manufacturing scale, and specific technical requirements. No public pricing tiers available.

medpharm.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Tergus Pharma is a contract development and manufacturing organization (CDMO) providing integrated topical and transdermal drug development and manufacturing services for pharmaceutical and biotech companies. Services span formulation development, analytical and bioanalytical testing, IVRT/IVPT performance testing, clinical trial material manufacturing, commercial-scale GMP manufacturing, packaging and serialization, and stability storage and testing across multiple delivery routes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • FDA inspection with zero Form 483 observations
+1 more record
Product overview1 text field

MedPharm (post-merger with Tergus Pharma) operates as an integrated topical and transepithelial CDMO (Contract Development and Manufacturing Organization) offering a comprehensive platform of drug development and manufacturing services. The platform consists of analytical and testing services (Analytical Services, Bioanalytical Services, Raw Material Testing, Stability Storage & Testing, Research Biology & Tissue Culture), formulation development services (Formulation Development, Generics & Value-Added Generics, IVRT/IVPT Performance Testing), manufacturing services (Clinical Trial Material Manufacturing, Commercial Manufacturing, Packaging and Serialization, Scale-Up & Process Development), and specialized delivery route expertise across eight routes including Dermal & Transdermal, Ungual, Ophthalmic, Respiratory, Mucosal, Otic, Gastrointestinal, and Vaginal. The combined entity leverages UK and US facilities to provide end-to-end capabilities from early-phase development through commercial production.

Product and service14 records
1Analytical Services
CategoryAnalytical & Testing
Description

Comprehensive analytical and testing services to support development, quality, and regulatory requirements, delivering reliable data to guide critical decisions for pharmaceutical and biotech clients.

2Bioanalytical Services
CategoryAnalytical & Testing
Description

Specialized bioanalytical testing services for drug development supporting pharmacokinetic and bioequivalence studies for pharmaceutical clients.

3Formulation Development
CategoryDrug Development
Description

Strategic formulation development for topical and transepithelial drug products, focused on optimizing delivery, stability, and patient performance for pharmaceutical and biotech sponsors.

4In Vitro Release Test (IVRT)
CategoryAnalytical & Testing
Description

In vitro release testing service to evaluate drug release characteristics from topical formulations for pharmaceutical and biotech clients.

5In Vitro Permeation Test (IVPT)
CategoryAnalytical & Testing
Description

In vitro permeation testing service to evaluate drug permeation through skin or other biological membranes for pharmaceutical sponsors.

6Scale-Up & Process Development
CategoryManufacturing Services
Description

Process development and scale-up services to translate formulations from lab to manufacturing, ensuring robust, reproducible performance at commercial scale.

7Clinical Trial Material Manufacturing
CategoryManufacturing Services
Description

Clinical trial material manufacturing and supply to support early- and late-stage studies, ensuring quality, consistency, and reliable delivery for pharmaceutical sponsors.

8Commercial Manufacturing
CategoryManufacturing Services
Description

Scalable GMP manufacturing for semi-solid and liquid drug products, supporting clinical supply through commercial production with quality and consistency.

9Packaging and Serialization
CategoryManufacturing Services
Description

Packaging and serialization solutions to support product integrity, compliance, and global distribution requirements for pharmaceutical clients.

10Stability Storage & Testing
CategoryAnalytical & Testing
Description

ICH-compliant stability studies to support product shelf-life, regulatory submissions, and ongoing commercial supply.

11Raw Material Testing
CategoryAnalytical & Testing
Description

Testing services for raw materials used in pharmaceutical manufacturing to ensure quality and compliance.

12Research Biology & Tissue Culture
CategoryDrug Development
Description

Research biology models and tissue culture services to evaluate pharmacological activity across development for pharmaceutical sponsors.

13Generics & Value-Added Generics
CategoryDrug Development
Description

Development services for generic topical and transdermal products with enhanced formulation characteristics, supporting bioequivalence and differentiation.

14Cosmetics & OTC
CategoryDrug Development
Description

Formulation development and manufacturing services for cosmetic and over-the-counter topical products.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-08
Description

Merger between Tergus Pharma (US-based) and MedPharm (UK-based CDMO) creating an integrated organization. The combined entity operates under the MedPharm name and offers comprehensive drug development and production services including expanded manufacturing capabilities for topical and transdermal drugs, hormone-based products, and highly potent drugs.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based CDMO specializing in topical and transdermal drug development and manufacturing; effectively the combined entity following the July 2024 merger with Tergus Pharma. Directly comparable in formulation science, IVRT/IVPT models, and GMP topical manufacturing capabilities.

2Tapemark
TypeDirect peer
Description

US-based contract manufacturer specializing in topical and transdermal drug products including patches, gels, and creams. Direct competitor for semi-solid and transdermal GMP manufacturing projects in North America.

TypeDirect peer
Description

Specialty CDMO focused on semi-solid and liquid pharmaceutical manufacturing, with strong capabilities in topical formulations, now operating within Sanofi's contract services business. Comparable in dosage form and customer base.

TypeBroad incumbent
Description

Large diversified CDMO with oral, sterile injectable, and topical capabilities including softgel and specialty dose manufacturing. Overlaps with Tergus on commercial topical and transdermal supply but serves a much broader customer base.

5Recipharm
TypeBroad incumbent
Description

European-headquartered CDMO offering development and manufacturing services across multiple dosage forms including topicals. Operates at larger scale with broader service portfolio but has overlapping topical formulation capabilities.

TypeBroad incumbent
Description

Specialty CDMO with strong capabilities in API and particle engineering alongside topical and inhaled drug product development. Comparable in highly potent compound handling and complex formulation science.

TypeBroad incumbent
Description

Small-molecule API and drug product CDMO with formulation and analytical services relevant to topical generics development. Now operating within Pfizer CentreOne, broader in scope but overlapping on formulation work.

TypeEmerging player
Description

CDMO offering formulation development, analytical services, and commercial manufacturing for solid, semi-solid, and liquid dosage forms. Emerging mid-tier peer with overlapping topical and specialty dose capabilities.

TypeBroad incumbent
Description

Global CDMO offering drug development, manufacturing, packaging, and serialization services across multiple dosage forms including topicals. Broad incumbent with commercial supply and packaging services that overlap with Tergus' late-stage offering.

TypeEmerging player
Description

CDMO focused on oral solid, semi-solid, and liquid dosage forms for pediatric and specialty pharmaceutical products. Emerging competitor in the topical and specialty formulation space with comparable customer profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tergus Pharma

Pharmaceutical CDMO Servicesterguspharma.com

Tergus Pharma is a US-based contract development and manufacturing organization (CDMO) specializing in topical and transdermal drug formulation, analytical testing, and GMP manufacturing for pharmaceutical and biotech clients across multiple delivery routes; the company merged with UK-based MedPharm in July 2024 and now operates under the MedPharm name.

What Tergus Pharma does

Tergus Pharma is a US-based contract development and manufacturing organization (CDMO) founded in 1994 and headquartered in Durham, North Carolina, specializing in topical and transdermal pharmaceutical drug development and manufacturing. The company operates two Durham facilities — a research and innovation center on Emperor Boulevard supporting early-phase formulation development and a Stirrup Creek Drive site for clinical trial material supply and commercial GMP production — and serves pharmaceutical and biotech clients requiring specialized formulation, analytical, scale-up, and manufacturing services across dermal, ungual, ophthalmic, respiratory, mucosal, otic, gastrointestinal, and vaginal delivery routes.

The company's core technology stack centers on proprietary formulation science and in vitro performance testing platforms, including In Vitro Release Testing (IVRT) and In Vitro Permeation Testing (IVPT) models plus specialized nail permeation testing for keratinized tissue delivery. GMP manufacturing capabilities cover semi-solid and liquid drug products with particular strength in hormone-based compounds and highly potent active pharmaceutical ingredients, supported by an FDA inspection that returned a No Action Indicated (NAI) classification with zero Form 483 observations. The service portfolio spans formulation development, analytical and bioanalytical services, raw material and stability testing, research biology and tissue culture, scale-up and process development, clinical trial material manufacturing, commercial manufacturing, packaging and serialization, and generics and value-added generics development.

Tergus generated revenue through professional services engagements — fee-for-service drug development contracts, project-based GMP manufacturing agreements, and integrated development-to-commercial packages — sold via direct enterprise field sales to pharmaceutical and biotech procurement and R&D teams. Pricing was project-quoted based on scope, complexity, and volume, with multi-year contract cadences typical for late-stage and commercial supply relationships. In July 2024, Tergus merged with UK-based MedPharm, a CDMO with overlapping topical and transdermal specialization, with the combined entity now operating under the MedPharm name and offering transatlantic research, clinical supply, and commercial manufacturing capabilities.

Tergus Pharma firmographics

Firmographics
Name
Tergus Pharma
Legal name
Tergus Pharma
Website
https://terguspharma.com
Company type
Private
Founded year
1994
Operating status
Acquired
Headcount range
11–50 employees
Short description
Tergus Pharma is a US-based contract development and manufacturing organization (CDMO) specializing in topical and transdermal drug formulation, analytical testing, and GMP manufacturing for pharmaceutical and biotech clients across multiple delivery routes; the company merged with UK-based MedPharm in July 2024 and now operates under the MedPharm name.
Ownership category
akta.pro rank

Tergus Pharma industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Topical drug development
  • Transdermal CDMO services
  • Pharmaceutical contract manufacturing
  • Formulation development services
  • GMP commercial manufacturing

Where Tergus Pharma is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Tergus Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: GMP manufacturing services for semi-solid and liquid drug products supporting clinical trial material supply and commercial production. Revenue generated through project-based contracts with pharmaceutical and biotech companies requiring manufacturing scale-up and commercial supply capabilities.
  2. Drug Development Services: Formulation development, analytical services, bioanalytical services, stability storage and testing, in vitro performance testing (IVRT/IVPT), and process development. Revenue derived from fee-for-service engagements across the drug development lifecycle from early phase through regulatory submission.
  3. Regulatory and Quality Services: Quality assurance, regulatory standards support, validation studies, and regulatory submission preparation. Integrated as part of development and manufacturing service packages.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based quoting for drug development and manufacturing services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Tergus Pharma product offering

Product offering

Core offering

Tergus Pharma is a contract development and manufacturing organization (CDMO) providing integrated topical and transdermal drug development and manufacturing services for pharmaceutical and biotech companies. Services span formulation development, analytical and bioanalytical testing, IVRT/IVPT performance testing, clinical trial material manufacturing, commercial-scale GMP manufacturing, packaging and serialization, and stability storage and testing across multiple delivery routes.

Product overview

MedPharm (post-merger with Tergus Pharma) operates as an integrated topical and transepithelial CDMO (Contract Development and Manufacturing Organization) offering a comprehensive platform of drug development and manufacturing services. The platform consists of analytical and testing services (Analytical Services, Bioanalytical Services, Raw Material Testing, Stability Storage & Testing, Research Biology & Tissue Culture), formulation development services (Formulation Development, Generics & Value-Added Generics, IVRT/IVPT Performance Testing), manufacturing services (Clinical Trial Material Manufacturing, Commercial Manufacturing, Packaging and Serialization, Scale-Up & Process Development), and specialized delivery route expertise across eight routes including Dermal & Transdermal, Ungual, Ophthalmic, Respiratory, Mucosal, Otic, Gastrointestinal, and Vaginal. The combined entity leverages UK and US facilities to provide end-to-end capabilities from early-phase development through commercial production.

Differentiator

Problem solved

Functional benefit

Products and services

  • Analytical Services Comprehensive analytical and testing services to support development, quality, and regulatory requirements, delivering reliable data to guide critical decisions for pharmaceutical and biotech clients.
  • Bioanalytical Services Specialized bioanalytical testing services for drug development supporting pharmacokinetic and bioequivalence studies for pharmaceutical clients.
  • Formulation Development Strategic formulation development for topical and transepithelial drug products, focused on optimizing delivery, stability, and patient performance for pharmaceutical and biotech sponsors.
  • In Vitro Release Test (IVRT) In vitro release testing service to evaluate drug release characteristics from topical formulations for pharmaceutical and biotech clients.
  • In Vitro Permeation Test (IVPT) In vitro permeation testing service to evaluate drug permeation through skin or other biological membranes for pharmaceutical sponsors.
  • Scale-Up & Process Development Process development and scale-up services to translate formulations from lab to manufacturing, ensuring robust, reproducible performance at commercial scale.
  • Clinical Trial Material Manufacturing Clinical trial material manufacturing and supply to support early- and late-stage studies, ensuring quality, consistency, and reliable delivery for pharmaceutical sponsors.
  • Commercial Manufacturing Scalable GMP manufacturing for semi-solid and liquid drug products, supporting clinical supply through commercial production with quality and consistency.
  • Packaging and Serialization Packaging and serialization solutions to support product integrity, compliance, and global distribution requirements for pharmaceutical clients.
  • Stability Storage & Testing ICH-compliant stability studies to support product shelf-life, regulatory submissions, and ongoing commercial supply.
  • Raw Material Testing Testing services for raw materials used in pharmaceutical manufacturing to ensure quality and compliance.
  • Research Biology & Tissue Culture Research biology models and tissue culture services to evaluate pharmacological activity across development for pharmaceutical sponsors.
  • Generics & Value-Added Generics Development services for generic topical and transdermal products with enhanced formulation characteristics, supporting bioequivalence and differentiation.
  • Cosmetics & OTC Formulation development and manufacturing services for cosmetic and over-the-counter topical products.

Quantifiable outcome

  • FDA inspection with zero Form 483 observations
  • +1 more outcomes

Companies that use Tergus Pharma

Customer profile

Segments3 records

Ideal customer profiles2 records

Tergus Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Tergus Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MedPharmcoreStrategic or Co-development Partner · 8 July 2024Merger between Tergus Pharma (US-based) and MedPharm (UK-based CDMO) creating an integrated organization. The combined entity operates under the MedPharm name and offers comprehensive drug development and production services including expanded manufacturing capabilities for topical and transdermal drugs, hormone-based products, and highly potent drugs.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Tergus Pharma competitors and assessment

Company assessment

Direct peers

  • MedPharm: UK-based CDMO specializing in topical and transdermal drug development and manufacturing; effectively the combined entity following the July 2024 merger with Tergus Pharma. Directly comparable in formulation science, IVRT/IVPT models, and GMP topical manufacturing capabilities.
  • Tapemark: US-based contract manufacturer specializing in topical and transdermal drug products including patches, gels, and creams. Direct competitor for semi-solid and transdermal GMP manufacturing projects in North America.
  • DPT Laboratories (Sanofi): Specialty CDMO focused on semi-solid and liquid pharmaceutical manufacturing, with strong capabilities in topical formulations, now operating within Sanofi's contract services business. Comparable in dosage form and customer base.

Broad incumbents

  • Catalent: Large diversified CDMO with oral, sterile injectable, and topical capabilities including softgel and specialty dose manufacturing. Overlaps with Tergus on commercial topical and transdermal supply but serves a much broader customer base.
  • Recipharm: European-headquartered CDMO offering development and manufacturing services across multiple dosage forms including topicals. Operates at larger scale with broader service portfolio but has overlapping topical formulation capabilities.
  • Hovione: Specialty CDMO with strong capabilities in API and particle engineering alongside topical and inhaled drug product development. Comparable in highly potent compound handling and complex formulation science.
  • Cambrex (Pfizer CentreOne): Small-molecule API and drug product CDMO with formulation and analytical services relevant to topical generics development. Now operating within Pfizer CentreOne, broader in scope but overlapping on formulation work.
  • PCI Pharma Services: Global CDMO offering drug development, manufacturing, packaging, and serialization services across multiple dosage forms including topicals. Broad incumbent with commercial supply and packaging services that overlap with Tergus' late-stage offering.

Emerging players

  • CoreRx Pharmaceuticals: CDMO offering formulation development, analytical services, and commercial manufacturing for solid, semi-solid, and liquid dosage forms. Emerging mid-tier peer with overlapping topical and specialty dose capabilities.
  • Halo Pharma (Aropha): CDMO focused on oral solid, semi-solid, and liquid dosage forms for pediatric and specialty pharmaceutical products. Emerging competitor in the topical and specialty formulation space with comparable customer profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Tergus Pharma social profiles

Digital presence

Tergus Pharma compliance and trust

Trust signal

Compliance1 record

Tergus Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tergus Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Tergus Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tergus Pharma M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tergus Pharma

What does Tergus Pharma do?

Tergus Pharma is a contract development and manufacturing organization (CDMO) providing integrated topical and transdermal drug development and manufacturing services for pharmaceutical and biotech companies. Services span formulation development, analytical and bioanalytical testing, IVRT/IVPT performance testing, clinical trial material manufacturing, commercial-scale GMP manufacturing, packaging and serialization, and stability storage and testing across multiple delivery routes.

Is Tergus Pharma a public or private company?

Tergus Pharma is a private company. It is classified as private equity controlled and is currently acquired.

When was Tergus Pharma founded?

Tergus Pharma was founded in 1994. It employs 11 to 50 people.

Where is Tergus Pharma based?

Tergus Pharma is headquartered in Durham, United States, in the North America region.

How does Tergus Pharma make money?

Three revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are drug Development Services and regulatory and Quality Services.

Who are Tergus Pharma's main competitors?

Direct peers on record are MedPharm, Tapemark and DPT Laboratories (Sanofi). Broad incumbents are Catalent, Recipharm, Hovione, Cambrex (Pfizer CentreOne) and PCI Pharma Services. Emerging players are CoreRx Pharmaceuticals and Halo Pharma (Aropha).

Does Tergus Pharma have an API?

No public API is recorded for Tergus Pharma.

What industry is Tergus Pharma in?

Tergus Pharma's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioPharm InternationalFormulation of Biologics for Non-Invasive DeliveryPharmaceutical industry experts discuss the technical challenges and emerging innovations in formulating biologic drugs for non-invasive delivery routes including oral, inhaled, nasal, topical, and microneedle methods. The article highlights that while the biologics market is projected to reach $399.5 billion by 2025, significant formulation hurdles remain around protein stability, degradation in the gastrointestinal tract, and penetration of biological barriers. Key technologies being developed include spray-dried particles for inhaled delivery, enteric-coated capsules for oral delivery, and microneedle patches for transdermal administration, with companies like Patheon, Capsugel/Lonza, Tergus Pharma, Intertek, and 3M presenting their respective delivery solutions.FinSMEsMedPharm and Tergus Pharma MergeMedPharm, a UK-based CDMO, has merged with Tergus Pharma, a US-based contract service provider, to form an integrated end-to-end CDMO operating under the MedPharm name. The combined entity will leverage expanded capabilities in drug development and manufacturing, including hormone-based and highly potent drugs at its Durham, NC facility. Private equity firms Ampersand Capital Partners and Bourne Partners Strategic Capital have assumed majority ownership of the merged organization.ThemiddlemarketAmpersand-Backed MedPharm and Great Point-Backed Tergus Pharma MergeMedPharm, backed by Ampersand Capital Partners, and Tergus Pharma, backed by Great Point Partners, have merged to form a combined contract development and manufacturing organization. The newly consolidated entity will operate under the MedPharm name.PrwebTergus Pharma, LLC Announces Addition of Key Executive Management PositionsTergus Pharma appointed James Wysocki as CFO and Alan Burns as VP of Quality and Regulatory Compliance. Wysocki previously led finance at Pfizer and Novartis, while Burns has over 25 years in quality and compliance. The company plans to expand into commercial manufacturing.GlobeNewswireTergus Pharma Announces New Commercial Manufacturing Facility and Partnership with Great Point PartnersTergus Pharma announced a 100,000-square-foot headquarters and plans to expand into commercial manufacturing, partnering with Great Point Partners for growth equity. The new facility will expand capacity by over 400% and begin construction in July 2019, opening in early 2020.GlobeNewswireTergus CEO to Speak at 5th Annual Innovations in Dermatological Sciences ConferenceTergus Pharma CEO Vijendra Nalamothu will speak at the 5th annual Innovations in Dermatological Sciences conference in Iselin, New Jersey, on September 29-30, 2016. He will discuss semi-solid drug product characterization using critical process and material attributes, with a focus on clinical de-risking and topical formulation strategies.GlobeNewswireTergus Hires Seasoned Director of Business DevelopmentTergus Pharma hired Graham Mott as Director of Business Development to lead sales and marketing. Mott holds a bachelor's from the University of Miami and an MBA from the University of Phoenix, with experience in dermatological markets. The company has grown its footprint, expanding to a 28,000-square-foot facility.GlobeNewswireTergus Creates Several Key Positions and Attracts Top TalentTergus Pharma hired James Varner as Senior Manager of Analytical R&D and Lance Rogers as Project Management Leader. Varner will lead late-stage development and optimization, while Rogers will grow the project management department. The hires support the company's growth and expansion.GlobeNewswireTergus Hires Top Manufacturing ExecutiveTergus Pharma hired Ashik Pavagadhi as Head of Manufacturing Operations, overseeing clinical supply manufacturing of topical pharmaceuticals. Pavagadhi brings over 18 years of experience, including roles at Heel, Chiron, and Stryker Biotech. The hiring reinforces Tergus's position as an industry leader in topical clinical supply manufacturing.GlobeNewswireTergus Hires Leading Sales and Marketing ExecutiveTergus hired Michele Nathan Borek as Director of Sales and Marketing, bringing over 20 years of life science marketing experience. The company, a leader in topical pharmaceutical development and cGMP clinical supply manufacturing, continues to expand its footprint and attract top talent.